CN101172103A - Medicament for treating multiple diseases such as climacteric syndrome and osteoporosis of women - Google Patents
Medicament for treating multiple diseases such as climacteric syndrome and osteoporosis of women Download PDFInfo
- Publication number
- CN101172103A CN101172103A CNA2007100174802A CN200710017480A CN101172103A CN 101172103 A CN101172103 A CN 101172103A CN A2007100174802 A CNA2007100174802 A CN A2007100174802A CN 200710017480 A CN200710017480 A CN 200710017480A CN 101172103 A CN101172103 A CN 101172103A
- Authority
- CN
- China
- Prior art keywords
- acid
- medicine
- percent
- treatment
- women
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 49
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 30
- 201000010099 disease Diseases 0.000 title claims abstract description 29
- 208000001132 Osteoporosis Diseases 0.000 title claims description 12
- 208000011580 syndromic disease Diseases 0.000 title abstract description 11
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 29
- 229930195729 fatty acid Natural products 0.000 claims abstract description 29
- 239000000194 fatty acid Substances 0.000 claims abstract description 29
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 29
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims abstract description 27
- 235000021314 Palmitic acid Nutrition 0.000 claims abstract description 13
- 208000002500 Primary Ovarian Insufficiency Diseases 0.000 claims abstract description 13
- 206010036601 premature menopause Diseases 0.000 claims abstract description 13
- 208000017942 premature ovarian failure 1 Diseases 0.000 claims abstract description 13
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 claims abstract description 12
- 208000024732 dysthymic disease Diseases 0.000 claims abstract description 12
- 206010020850 Hyperthyroidism Diseases 0.000 claims abstract description 10
- NNNVXFKZMRGJPM-KHPPLWFESA-N sapienic acid Chemical compound CCCCCCCCC\C=C/CCCCC(O)=O NNNVXFKZMRGJPM-KHPPLWFESA-N 0.000 claims abstract description 10
- ADHNUPOJJCKWRT-JLXBFWJWSA-N (2e,4e)-octadeca-2,4-dienoic acid Chemical compound CCCCCCCCCCCCC\C=C\C=C\C(O)=O ADHNUPOJJCKWRT-JLXBFWJWSA-N 0.000 claims abstract description 8
- 241000229143 Hippophae Species 0.000 claims description 33
- 239000002253 acid Substances 0.000 claims description 23
- 235000013399 edible fruits Nutrition 0.000 claims description 19
- 206010036618 Premenstrual syndrome Diseases 0.000 claims description 10
- 241000196324 Embryophyta Species 0.000 claims description 9
- 210000004209 hair Anatomy 0.000 claims description 8
- LKOVPWSSZFDYPG-WUKNDPDISA-N trans-octadec-2-enoic acid Chemical compound CCCCCCCCCCCCCCC\C=C\C(O)=O LKOVPWSSZFDYPG-WUKNDPDISA-N 0.000 claims description 8
- 201000004384 Alopecia Diseases 0.000 claims description 7
- 231100000360 alopecia Toxicity 0.000 claims description 7
- 150000002885 octadecanoids Chemical class 0.000 claims description 7
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 claims description 4
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 claims description 4
- 241000628997 Flos Species 0.000 claims description 4
- 235000008384 feverfew Nutrition 0.000 claims description 4
- 206010027304 Menopausal symptoms Diseases 0.000 claims description 3
- 241001233957 eudicotyledons Species 0.000 claims description 3
- 240000004460 Tanacetum coccineum Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 22
- 239000000126 substance Substances 0.000 abstract description 4
- 208000024891 symptom Diseases 0.000 abstract description 3
- DQGMPXYVZZCNDQ-KBPWROHVSA-N (8E,10E,12Z)-octadecatrienoic acid Chemical compound CCCCC\C=C/C=C/C=C/CCCCCCC(O)=O DQGMPXYVZZCNDQ-KBPWROHVSA-N 0.000 abstract 1
- OXEDXHIBHVMDST-UHFFFAOYSA-N 12Z-octadecenoic acid Natural products CCCCCC=CCCCCCCCCCCC(O)=O OXEDXHIBHVMDST-UHFFFAOYSA-N 0.000 abstract 1
- DQGMPXYVZZCNDQ-UVZPLDOLSA-N Calendinsaeure Natural products CCCCCC=C/C=C/C=C/CCCCCCC(=O)O DQGMPXYVZZCNDQ-UVZPLDOLSA-N 0.000 abstract 1
- 208000007984 Female Infertility Diseases 0.000 abstract 1
- 206010021928 Infertility female Diseases 0.000 abstract 1
- 241000251953 Leucotrichia Species 0.000 abstract 1
- 208000007466 Male Infertility Diseases 0.000 abstract 1
- 235000021355 Stearic acid Nutrition 0.000 abstract 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 abstract 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 230000002441 reversible effect Effects 0.000 abstract 1
- 235000003935 Hippophae Nutrition 0.000 description 19
- 238000000034 method Methods 0.000 description 16
- 239000000203 mixture Substances 0.000 description 16
- 239000003921 oil Substances 0.000 description 16
- 229940079593 drug Drugs 0.000 description 12
- 230000003203 everyday effect Effects 0.000 description 12
- 238000000605 extraction Methods 0.000 description 11
- 230000006870 function Effects 0.000 description 10
- 235000003145 Hippophae rhamnoides Nutrition 0.000 description 7
- 208000000509 infertility Diseases 0.000 description 7
- 230000036512 infertility Effects 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 6
- 125000001931 aliphatic group Chemical group 0.000 description 5
- 208000021267 infertility disease Diseases 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 230000000750 progressive effect Effects 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 102000010909 Monoamine Oxidase Human genes 0.000 description 4
- 108010062431 Monoamine oxidase Proteins 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 235000021022 fresh fruits Nutrition 0.000 description 4
- 230000037308 hair color Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 235000002566 Capsicum Nutrition 0.000 description 3
- 244000192528 Chrysanthemum parthenium Species 0.000 description 3
- 244000166124 Eucalyptus globulus Species 0.000 description 3
- 239000006002 Pepper Substances 0.000 description 3
- 241000722363 Piper Species 0.000 description 3
- 235000016761 Piper aduncum Nutrition 0.000 description 3
- 235000017804 Piper guineense Nutrition 0.000 description 3
- 235000008184 Piper nigrum Nutrition 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000021595 spermatogenesis Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- -1 16:0) Chemical compound 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 235000021319 Palmitoleic acid Nutrition 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 2
- 238000000199 molecular distillation Methods 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000003815 supercritical carbon dioxide extraction Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- ZVRMGCSSSYZGSM-CCEZHUSRSA-N (E)-hexadec-2-enoic acid Chemical compound CCCCCCCCCCCCC\C=C\C(O)=O ZVRMGCSSSYZGSM-CCEZHUSRSA-N 0.000 description 1
- YZAZXIUFBCPZGB-QZOPMXJLSA-N (z)-octadec-9-enoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O YZAZXIUFBCPZGB-QZOPMXJLSA-N 0.000 description 1
- 102000005606 Activins Human genes 0.000 description 1
- 108010059616 Activins Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 240000000950 Hippophae rhamnoides Species 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- SNIXRMIHFOIVBB-UHFFFAOYSA-N N-Hydroxyl-tryptamine Chemical compound C1=CC=C2C(CCNO)=CNC2=C1 SNIXRMIHFOIVBB-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 230000003679 aging effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 230000000776 anti-sterility effect Effects 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000019987 cider Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000881 depressing effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000002768 hair cell Anatomy 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000019616 numbness Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- RQFLGKYCYMMRMC-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O RQFLGKYCYMMRMC-UHFFFAOYSA-N 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 230000001009 osteoporotic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 229940120293 vaginal suppository Drugs 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to medicine for remedying women climacteric syndrome, osteoprosis, dysthymia, premature ovarian failure, premenstruum stress syndrome, hyperthyroidism, male and female Female/male infertility symptom, alopeia and leucotrichia and other diseases. The utility model is characterized in that the medicine comprises fatty acid within the scope of following weight parts: 8 to 32 percent of hexadecanoic acid, 11 to 35 percent of hexadecenoic acid, 13 to 33 percent of octadecenic acid, 0.3 to 2.5 percent of octadecanoic acid, 11 to 33 percent of octadecadienoic acid and 3 to 15 percent of calendic acid. Compared with other medicine, the medicine has simple component, belongs to target organ excitant, and has the function of self reversible adjustment to the second messenger substance of the organism. The invention belongs to medicine with high, safe and streamlined curative effect.
Description
Technical field
The invention belongs to aliphatic acid composition, especially for the fatty acid medicine of multiple diseases such as treatment climacteric syndrome, osteoporosis, dysthymia, premature ovarian failure, premenstrualtension syndrome, hyperthyroidism, men and women's property barrenness, alopecia and white hair.
Background technology
The inventor is engaged in the interior biochemistry of herbal pharmacology, active ingredient, body of seabuckthorn plant and the basis and the applied research work of Nutrition and Metabolism aspect for a long time.In medical practice for many years, examine thousands of examples and took the patient of Oleum Hippophae for a long time, comprised the patient of multiple diseases such as menopausal syndrome, osteoporosis, dysthymia, premature ovarian failure, premenstrualtension syndrome, hyperthyroidism, men and women's property barrenness, alopecia and white hair.On the basis of observing extensively and profoundly, find that Fructus Hippophae extract such as Oleum Hippophae have certain effect to treating above-mentioned various disease.Again the upright project of attaching most importance to of this problem is studied targetedly afterwards., be better than existing various medicine, thereby can be used as this type of sick medicine of treatment after a large amount of evidence truly has better curative effect to these diseases.On this basis, the inventor applied for the drug patent of multinomial relevant Fructus Hippophae treatment various diseases, as CN94118300, CN2005100962820, CN200510096282, CN03134522 etc.Subsequently in further further investigation Fructus Hippophae medicine therapy mechanism process, found the effective ingredient of curing the disease in the seabuckthorn plant gradually, this is significant in the medicine and pharmacology field.Treating above-mentioned various disease is the great difficult medical problem in the world today, also is that people thirst for solving always but do not obtain the difficult medical problem of satisfactory result all the time.The existing situation of relevant these diseases of treatment can repeat no more referring to all kinds of patents of my application.
Up to now, except that the patent of my application, still there is not the Drugdoc report of multiple diseases such as adopting Oleum Hippophae, leaf oil or full fruit oil treatment climacteric syndrome, osteoporosis, dysthymia, premature ovarian failure, premenstrualtension syndrome, hyperthyroidism, men and women's property barrenness, alopecia and white hair both at home and abroad.So far also do not have on the market comparatively ideal prevent above-mentioned disease safely, the medicine of simplifying.
Summary of the invention
The objective of the invention is to overcome the deficiency of existing Chinese and western drugs Therapeutic Method, a kind of fatty acid medicine for the treatment of multiple diseases such as climacteric syndrome, osteoporosis, dysthymia, premature ovarian failure, premenstrualtension syndrome, hyperthyroidism, sterility or barrenness of man and women, alopecia and white hair is provided, curative effect is better than existing various kinds of drug, and is also safer.
The seabuckthorn plant complicated component.Determine wherein which composition is the active ingredient of treatment disease, is very difficult large order.For this reason, the inventor is on the basis of Fructus Hippophae that studies for a long period of time, at last with the fatty acid of Fructus Hippophae extract specific group composition and certain content ratio as medicine, signal transduction pathway by the fatty acid medicine is regulated the cell function of body, and is exciting or suppress the function of receptors of body and reach the purpose of medical treatment disease.Propose first seabuckthorn plant treat above-mentioned disease active ingredient be the aliphatic acid composition of special constituent ratio and the pharmacological action by signal transduction pathway medical treatment disease thereof.
Through constantly test, adjust prescription, improve and improve, be prepared into the medicine of multiple diseases such as a kind of extensive treatment climacteric syndrome, osteoporosis, dysthymia, premature ovarian failure, premenstrualtension syndrome, hyperthyroidism, sterility or barrenness of man and women, alopecia and white hair finally.The composition prescription of this medicine is mainly by hexadecanoic acid (palmitic acid Palmic acid, 16:0), hexadecenoic acid (palmitoleic acid Palmitoleicacid or title hexadecenoic acid 16 (carbon) olefin(e) acid, 16:1n-7), octadecenoic acid (oleic acid Oleic acid, 18:1n-9), octadecanoid acid (stearic acid stearic acid, 18:0), octadecadienoic acid (linoleic acid linoleic Acid, 18:2n-6) and jeceric acid (linolenic acid linolenic Acid 18:3n-3) waits six kinds of fatty acids to form.The weight percentage ranges that it is characterized in that preparing the various fatty acids of preparation is:
Hexadecanoic acid 8～32%
Hexadecenoic acid 11～35%
Octadecenoic acid 13～33%
Octadecanoid acid 0.3～2.5%
Octadecadienoic acid 11～33%
Jeceric acid 3～15%
Preferable medicament composing prescription is made up of the fatty acid of following weight percent values:
Hexadecanoic acid 23%
Hexadecylenic acid 4%
Octadecenoic acid 25%
Octadecanoid acid 1%
Octadecadienoic acid 21%
Jeceric acid 6%
Only need six kinds of liquid fat acid mix homogeneously are got final product.
The scope of above-mentioned ratio of components, particularly preferable medicine composition side has significant pharmacological action and has the function of the above-mentioned disease of medical treatment.Six kinds of fatty acid compositions are by its pharmacological action of preparation and the purposes for the treatment of disease than preparation of this specific structure, and all the research work by inventor's recent two decades confirms.This type of fatty acid all can be by extracting in the sea buckthorn fruit, also can from other plant, part obtain, can be from the son of Cortex Eucommiae plant, leaf as hexadecanoic acid and hexadecenoic acid, from the seed of dicotyledon medicine feverfew Flos Carthami fruit, from pepper seed skin wet goods plant and from the Eucalyptus blade, obtain respectively.Certainly also can make by chemical method.As long as they by proportioning combination of the present invention, are all had same effect.
Test shows, the above-mentioned fatty acid mixt that goes out from Oleum Hippophae, leaf oil and full fruit oil extraction separation, or from the son of Cortex Eucommiae plant, leaf, from the seed of dicotyledon medicine feverfew Flos Carthami fruit, from pepper seed skin wet goods plant and fatty acid compositions such as the hexadecanoic acid that from the Eucalyptus blade, obtains respectively, hexadecenoic acid, octadecenoic acid, to described various treatment of conditions can both obtain with Oleum Hippophae, leaf oil and full fruit oil quite or similar effects.The mixture of the fatty acid that explanation is extracted from plant must reach the effect of better treatment disease with signal transduction and the regulating action of specific composition than ability synergism performance medicine.Other structure ratio content of other fatty acid or identical fatty acid then may not have such effect.
The present invention has experienced the research process of recent two decades, and complete pharmacological experiment result and clinical research result are arranged.As treatment for depression, confirm that said composition is the Role in Plant Signal Transduction by the Oleum Hippophae fatty acid, the hormonal system of obvious human activin, activate function of receptors such as cyclic nucleotide and differential protein and make body produce endogenous material dopamine and materials such as five hydroxytryptamine and monoamine oxidase, MAO with two-ways regulation function, thus the treatment depression.(, confirming fruit oil or reach full fruit oil itself not contain materials such as dopamine, penta hydroxy group tryptamines and monoamine oxidase, MAO) through with gas phase, the analysis of contrasting property of liquid phase chromatography analytical method.
The real oil of said sea-buckthorn whole fruit is meant the mixed oil (main component be fatty acid mixt) of full fruit (comprising sarcocarp, seed, peel) with organic solvent extraction among the present invention.General with organic solvent chloroform, just own gastral cavity and No. four solvents etc., under temperature 30-70 ℃, pressure 0.3MPa-1.0MPa, from the full sea buckthorn fruit of drying and crushing, extract and make.Oleum Hippophae is meant the fruit juice oil that extracts or exempts from the fruit oil that heating is extracted through the physics centrifugalize from puree (the fresh fruit bits after fresh fruit presses fruit for cider) from the seabuckthorn plant fresh fruit.Also can adopt several different methods extraction separation from the Fructus Hippophae fatty oil such as physical extraction method, organic solvent extractionprocess, supercritical carbon dioxide extraction method, molecular distillation technique, continuous flow upstream dynamic extraction technology and gas-liquid permeability and separation method to obtain fatty acid afterwards.These all belong to prior art, need not to give unnecessary details.
Also all belong to prior art from the seed of the Cortex Eucommiae, medicine feverfew Flos Carthami fruit, pepper seed skin and the method for from the Eucalyptus blade, extracting fatty acid, do not give unnecessary details.
Research also confirms: chemical substance hexadecanoic acid, hexadecenoic acid, octadecenoic acid, octadecanoid acid, octadecadienoic acid, jeceric acid can be suitable with the real fatty acid oil content ratio of sea-buckthorn whole fruit behind suitable compatibility, and curative effect is also suitable.Can referring to I the application in order to the treatment climacteric syndrome, hyperthyroidism, premenstrualtension syndrome, the patent CN 94118300 of premature ovarian failure; The patent CN2005100962820 that is used for the treatment of the aging medicine of osteoporosis and bone; The patent CN200510096282 that is used for the treatment of dysthymia; Hair color and defying age patent CN03134522; Short male's spermatogenesis of preparation generates short women's follicle generation and both sexes aphoria and infertility patent CN200610105362 etc.The function and usage content of the Chemical composition that of six kinds of fatty acids of this patent can be enclosed as required at any time.Because of length is huge, wouldn't be attached.
Above-mentioned aliphatic acid composition such as hexadecanoic acid and hexadecenoic acid, through animal pharmacodynamics and clinical verification: (1) to treatment Woman climacteric battle array antiperspirant, warm, irritated irritability, insomnia, symptom such as forgetful have significant improvement and therapeutical effect; (2) the mood agitation that premenstrualtension syndrome is caused, spirit depressing, symptoms such as headache premenstruum have significant improvement and therapeutical effect; (3) can significantly reduce climacteric hyperthyroidism disease human serum T3, T4 level; (4) have the women's ovary of inhibition granular cell apoptosis, the function of the anti-premature ovarian failure of tool; (5) can improve body estrogen (α β) receptor by significance, the vit D3 receptor function has the aging and osteoporotic effect of anti-bone to aged body; (6) but significance increases male rat spermatogenesis daughter cell and spermatogenesis quantum count, significance promotes the generation of women and old female rats (18 monthly age) follicle quantity, has the function of anti-sterility or barrenness of man and women; (7) can significance improve body hairs and organize the CAMP level, make the hyaluronic acid enzyme-deactivating, the too fast hypertrophy of blocking-up hair cell improves the content of bone propylhomoserin enzyme, promotes melanin synzyme in the cell, thereby promotes melanic formation and bring into play the function of additional issue hair color.(this granted patent purposes confirms through basis and clinical research)
The specific embodiment
What test was taken is the preferable medicament composing prescription of the aforementioned six kinds of fatty acids of Oleum Hippophae.
1. treatment climacteric syndrome, anti-bone wear out and reach osteoporosis, additional issue hair color, premenstrual tension syndrome etc.Instructions of taking: obey 3 grams-5.4 grams every day.
Woman climacteric case observation of curative effect (313 example), take medicine by the following method:
Obey 5.4 grams every day, obey 1.8 grams at every turn, obey every day 3 times.3 months courses of treatment.MethodsThe cases enrolled 313 examples, the mean age is 48 ± 3.22 years old; 62 examples that the state of an illness is slight; Moderate 203 examples; Severe 38 examples.Add up after March through medication treatment: produce effects 212 people, progressive 83 people, invalid 18 people, obvious effective rate 68.73%, effective percentage 94.24%;
Aging and the osteoporosis case observation of curative effect (120 example) of the anti-bone of human body is taken medicine by the following method
Obey the 3.6-5.4 gram every day, obey 1.8 grams at every turn, obey 2-3 every day.3 months courses of treatment.MethodsThe cases enrolled 200 examples, the mean age is 50 ± 2.62 years old; 36 examples that the state of an illness is slight; Moderate 124 examples; Severe 40 examples.Add up after March through medication treatment: produce effects 138 people, progressive 43 people, invalid 19 people, obvious effective rate 69%, effective percentage 90.5%.
Human body additional issue, hair color case observation of curative effect (60 example) are taken medicine by the following method
Instructions of taking 1: obey the 3.6-5.4 gram every day, obey 1.8 grams at every turn, obey 2-3 every day.3 months courses of treatment.MethodsThe cases enrolled 60 examples, the mean age is 65 ± 3.18 years old; 5 examples that the state of an illness is slight; Moderate 45 examples; Severe 10 examples.Add up after March through medication treatment: produce effects 45 people, progressive 12 people, invalid 7 people, obvious effective rate 75%, effective percentage 93.33％；
2. treat dysthymia, premature ovarian failure, sterility or barrenness of man and women.Instructions of taking: obey 4.5 grams-7 grams every day.
The anti-dysthymia case of human body observation of curative effect (60 example) is taken medicine by the following method
Obey 6 grams every day, obey 2 grams at every turn, obey every day 3 times.3 months courses of treatment.MethodsThe cases enrolled 60 examples, the mean age is 47 ± 2.22 years old; 11 examples that the state of an illness is slight; Moderate 38 examples; Severe 11 examples.Add up after March through medication treatment: produce effects 49 people, progressive 5 people, invalid 6 people, obvious effective rate 88%, effective percentage 90%;
The anti-premature ovarian failure case of human body observation of curative effect (60 example) is taken medicine by the following method
Obey 5.4 grams every day, obey 1.8 grams at every turn, obey every day 3 times.3 months courses of treatment.MethodsThe cases enrolled 60 examples, the mean age 39.±2。1 year old; 7 examples that the state of an illness is slight; Moderate 43 examples; Severe 10 examples.Add up after March through medication treatment: produce effects 37 people, progressive 19 people, invalid 4 people, obvious effective rate 61.6%, effective percentage 93.33％；
Human body barrenness observation of curative effect (100 example): 46% obtain fertility among the infertility experimenter clinically.Other 58 obvious improvers of experimenter's self-induction function have 33 people, and it is about 20% that the sexual life number of times on average increases, and life quality generally improves.All the other people also have to a certain degree improvement.9 people's numbnesss only.Take continuously more than 3 years, do not find any side effect, belong to safe drugs.
At different syndromes, the portfolio ratio of six kinds of fatty acids can have certain variation.Experimentation confirms, dysthymia, premature ovarian failure, sterility or barrenness of man and women are the relation that dose-effect increases with the dosage increase.(, above-mentioned disease is all shown good result at aforementioned proportion.The length relation is not given unnecessary details)
The preparation of forming branch and special ratios compatibility by six kinds of fatty acids of the present invention can both obtain and the similar good result of Oleum Hippophae.As space is limited, can not contrast one by one.Relevant further detailed pharmacological action and drug efficacy study data all can be enclosed at any time, and be for reference.Here need to prove that aliphatic acid compositions such as hexadecanoic acid and carbon gaidic acid than combination, then do not have above-mentioned curative effect not according to the specific structure of this patent substantially.
For ease of oral or external, these aliphatic acid compositions can be prepared into multiple dosage forms such as soft capsule, oral liquid and solid hard capsule, external vaginal suppository.
This patent is on the basis to the research of seabuckthorn plant effective ingredient, and the fatty acid of discovery is formed branch and had the new types of drugs of therapeutic use aspect the multiple disease.
Seabuckthorn plant belongs to Elaeangnaceae, machaka or dungarunga.The used Fructus Hippophae kind of the present invention is Chinese sea buckthorn (Hippophae rhamnoides L sinesp sinensis Rousi), generally is distributed in provinces and regions such as northwest, northeast, Gansu, Shanxi and Inner Mongol.
The extraction process of Oleum Hippophae adopts the physical extraction method.Its method is: with sea-buchthorn fresh fruit
Place dull and stereotyped squeezer to squeeze, juice is by filling formula filter, the fine straining 4 times of pressurizeing continuously, and pressurization at last enters newborn ester formula centrifuge and separates, and can obtain Oleum Hippophae.
From the real oil of sea-buckthorn whole fruit, six kinds of fatty acids of plants such as puree oil, leaf oil preparation also can adopt several different methods extraction separation from the Fructus Hippophae fatty oil such as physical extraction method, organic solvent extractionprocess, supercritical carbon dioxide extraction method, molecular distillation technique, continuous flow upstream dynamic extraction technology and gas-liquid permeability and separation method to obtain fatty acid.The professional person all can implement, and does not give unnecessary details.
Up to now, still there is not the reported in literature that adopts specific structure to comprise multiple diseases such as climacteric syndrome, osteoporosis, dysthymia, premature ovarian failure, premenstrualtension syndrome, hyperthyroidism, sterility or barrenness of man and women, alopecia and white hair than Falty acid treatment both at home and abroad.Seemingly also there is not better medicine on the market.The dosage form of utilizing the present invention to prepare has been verified really and can have been treated multiple disease.Genus is simplified, safe drugs.Be the new invention that field of medicaments has important value, for finding first both at home and abroad and disclosing.
Claims (3)
1. medicine for the treatment of multiple diseases such as menopausal syndrome, osteoporosis, dysthymia, premature ovarian failure, premenstrualtension syndrome, hyperthyroidism, men and women's property barrenness, alopecia and white hair is characterized in that it is made up of the fatty acid of following percentage by weight:
Hexadecanoic acid 8～32%
Hexadecenoic acid 11～35%
Octadecenoic acid 13～33%
Octadecanoid acid 0.3～2.5%
Octadecadienoic acid 11～33%
Jeceric acid 3～15%
2. the medicine of the multiple disease of treatment as claimed in claim 1 is characterized in that it is made up of the fatty acid of following percentage by weight:
Hexadecanoic acid 23%
Hexadecylenic acid 4%
Octadecenoic acid 25%
Octadecanoid acid 1%
Octadecadienoic acid 21%
Jeceric acid 6%
3. the medicine of the multiple disease of treatment as claimed in claim 1 or 2 is characterized in that said hexadecanoic acid, hexadecenoic acid, octadecenoic acid, octadecanoid acid, octadecadienoic acid, jeceric acid are extracted by the seed of son, leaf and the dicotyledon medicine feverfew Flos Carthami fruit of fruit oil, leaf oil, full fruit oil and the Cortex Eucommiae plant of natural hippophae plant.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007100174802A CN101172103B (en) | 2007-03-12 | 2007-03-12 | Medicament for treating multiple diseases such as climacteric syndrome and osteoporosis of women |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007100174802A CN101172103B (en) | 2007-03-12 | 2007-03-12 | Medicament for treating multiple diseases such as climacteric syndrome and osteoporosis of women |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101172103A true CN101172103A (en) | 2008-05-07 |
| CN101172103B CN101172103B (en) | 2010-09-22 |
Family
ID=39420993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007100174802A Expired - Fee Related CN101172103B (en) | 2007-03-12 | 2007-03-12 | Medicament for treating multiple diseases such as climacteric syndrome and osteoporosis of women |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101172103B (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102188416A (en) * | 2011-03-25 | 2011-09-21 | 陕西天奎生物医药科技有限公司 | Medicine controlling and curing chronic aplastic anemia |
| WO2017005159A1 (en) * | 2015-07-06 | 2017-01-12 | 陕西天奎生物医药科技有限公司 | Natural pharmaceutical composition for treating osteoporotic fracture and/or osteoarthritis and use thereof |
| WO2017008737A1 (en) * | 2015-07-14 | 2017-01-19 | 陕西天奎生物医药科技有限公司 | A natural medicinal composition for treating involutional melancholia and atypical depressive disorder and use thereof |
| CN109106733A (en) * | 2017-06-22 | 2019-01-01 | 陕西天奎生物医药科技有限公司 | A kind of composition for preventing and treating diabetes and/or vascular complication disease, drug or health care product and its application |
| CN111789833A (en) * | 2020-08-31 | 2020-10-20 | 苏州大学 | Application of 2-bromopalmitic acid in preparation of medicine for preventing and treating bone loss related diseases |
| CN114392294A (en) * | 2021-11-09 | 2022-04-26 | 浙江中医药大学附属第二医院 | Edible paste for preventing and treating postmenopausal osteoporosis and preparation method thereof |
-
2007
- 2007-03-12 CN CN2007100174802A patent/CN101172103B/en not_active Expired - Fee Related
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102188416A (en) * | 2011-03-25 | 2011-09-21 | 陕西天奎生物医药科技有限公司 | Medicine controlling and curing chronic aplastic anemia |
| WO2017005159A1 (en) * | 2015-07-06 | 2017-01-12 | 陕西天奎生物医药科技有限公司 | Natural pharmaceutical composition for treating osteoporotic fracture and/or osteoarthritis and use thereof |
| CN106333977A (en) * | 2015-07-06 | 2017-01-18 | 陕西天奎生物医药科技有限公司 | Natural drug composition for treatment of osteoporotic fracture and/or osteoarthritis and application thereof |
| CN106333977B (en) * | 2015-07-06 | 2020-02-21 | 陕西天奎生物医药科技有限公司 | Natural pharmaceutical composition for treating osteoporotic fracture and/or osteoarthritis and application thereof |
| WO2017008737A1 (en) * | 2015-07-14 | 2017-01-19 | 陕西天奎生物医药科技有限公司 | A natural medicinal composition for treating involutional melancholia and atypical depressive disorder and use thereof |
| CN109106733A (en) * | 2017-06-22 | 2019-01-01 | 陕西天奎生物医药科技有限公司 | A kind of composition for preventing and treating diabetes and/or vascular complication disease, drug or health care product and its application |
| CN111789833A (en) * | 2020-08-31 | 2020-10-20 | 苏州大学 | Application of 2-bromopalmitic acid in preparation of medicine for preventing and treating bone loss related diseases |
| CN114392294A (en) * | 2021-11-09 | 2022-04-26 | 浙江中医药大学附属第二医院 | Edible paste for preventing and treating postmenopausal osteoporosis and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101172103B (en) | 2010-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101006693B1 (en) | Cosmetic compositions improving atopic dermatitis by complex function of damaged skin barrier repairing by lipid exchange and desensitizing, anti-inflammation and its manufacturing method thereof | |
| CN101172103B (en) | Medicament for treating multiple diseases such as climacteric syndrome and osteoporosis of women | |
| RU2011107255A (en) | APPLICATION OF A TRADITIONAL CHINESE MEDICINAL COMPOSITION FOR PRODUCING A MEDICINAL PRODUCT FOR PROMOTING SURVIVAL IN VIVO OBTAINED FROM BONE MARROW OF MESENCHYMAL STEM CELLS AND THEIR DIFFERENCIENCY VITIA | |
| CN104095231B (en) | A kind of health products containing agate coffee, the stem of noble dendrobium, American Ginseng and preparation method thereof | |
| CN104107299A (en) | Traditional Chinese medicine mixture for treating dysmenorrhoea | |
| US11129863B2 (en) | Composition, preparation method thereof, and application thereof in the prevention and treatment of mammary gland disease | |
| AU2012228213B2 (en) | Treatment of vaginal atrophy as novel indication for myrrh | |
| CN102038778B (en) | Chinese medicinal composition with effects of relaxing meridians, activating collaterals, expelling wind and removing dampness and preparation method thereof | |
| JP6280685B2 (en) | Tie2 activator, angiogenesis inhibitor, vascular maturation agent, vascular normalization agent, and vascular stabilization agent | |
| KR20150033797A (en) | Pharmaceutical composition for prevention and treatment of atopic skin disease | |
| KR20130040664A (en) | A cosmetic composition comprising an extract of rhus verniciflua stokes for trichogenousness | |
| CN110731953A (en) | Traditional Chinese medicine compound cataplasm for treating qi-stagnation and blood stasis type cervical spondylosis and preparation method thereof | |
| CN101361950A (en) | Gynaecologic traditional Chinese medicine capable of dispelling coldness, promoting blood and alleviating pain and preparation method thereof | |
| Ghasemzadeh Rahbardar et al. | Therapeutic potential of hypnotic herbal medicines: A comprehensive review | |
| CN104288390A (en) | Preparation method for medicine capable of treating cerebral infarction | |
| CN113456778A (en) | Composition for improving energy and preparation method thereof | |
| CN102961633B (en) | A kind of preparation for being used to treat postpartum rheumatism | |
| CN102048824B (en) | Traditional Chinese medicine composition for treating cerebrovascular disease and application thereof | |
| CN105055691A (en) | Traditional Chinese medicine composition efficient in overcoming erectile dysfunction in elderly male | |
| CN102552353A (en) | Chinese medicinal composition containing Chinese angelica and preparation method thereof | |
| RU2256462C1 (en) | Homeopathic suppository "hemoprost" (variants) | |
| CN111297971B (en) | Composition for treating breast cancer and preparation method and application thereof | |
| KR102145079B1 (en) | Compounds from the fruits of acrocomia crispa and acrocomia aculata against inflammation and oxidative stress | |
| Saad et al. | Tradition and Perspectives of Greco‐Arab and Islamic Herbal Medicine | |
| CN107929474B (en) | Pharmaceutical composition for treating depression |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160120 Address after: 710061 Xi'an Jiao Tong University medical school, 205 rosefinch Avenue, Yanta District, Shaanxi, Xi'an Patentee after: SHAANXI TIANKUI BIOMEDICINE TECHNOLOGY Ltd. Address before: 710061 Xi'an branch of Yanta West Road, Shaanxi 76, Xi'an Institute of medical biotechnology, Chinese Academy of Medical Sciences Patentee before: Wei Xiaqin |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Drugs for the treatment of menopausal syndrome and osteoporosis Effective date of registration: 20201116 Granted publication date: 20100922 Pledgee: Shaanxi Shixing Electronic Technology Co.,Ltd. Pledgor: SHAANXI TIANKUI BIOMEDICINE TECHNOLOGY Ltd. Registration number: Y2020610000205 |
|
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: Wei Xiaqin Document name: payment instructions |
|
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: Wei Xiaqin Document name: Notification of Conformity |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230504 Address after: Room 806, 8th Floor, Building 1, No. 111 Hongxing Road, Qiaonan Block, Economic and Technological Development Zone, Xiaoshan District, Hangzhou City, Zhejiang Province, 311217 Patentee after: Zhejiang Innovation Wisdom Valley Technology Co.,Ltd. Address before: 710061 Xi'an Jiaotong University School of Medicine, No.205 Zhuque Street, Yanta District, Xi'an City, Shaanxi Province Patentee before: SHAANXI TIANKUI BIOMEDICINE TECHNOLOGY Ltd. |
|
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: Zhejiang Innovation Wisdom Valley Technology Co.,Ltd. Person in charge of patents Document name: Notice of Termination of Patent Rights |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100922 |